INHIBITORS OF ERK AND METHODS OF USE

(19)

(11)

EP 3 052 096 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	07.03.2018 Bulletin 2018/10

(45)	Mention of the grant of the patent:
	17.01.2018 Bulletin 2018/03

(21)	Application number: 14850964.9

(22)	Date of filing: 03.10.2014

(51)

International Patent Classification (IPC):

C07D 471/04^(2006.01)
C07D 487/04^(2006.01)
A61K 31/437^(2006.01)

A61P 35/00^(2006.01)
A61K 31/519^(2006.01)

(86)	International application number:
	PCT/US2014/059197

(87)	International publication number:
	WO 2015/051341 (09.04.2015 Gazette 2015/14)

(54)	INHIBITORS OF ERK AND METHODS OF USE INHIBITOREN VON ERK UND VERFAHREN ZUR VERWENDUNG INHIBITEURS D'ERK ET MÉTHODES D'UTILISATION

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:
	BA ME

(30)

Priority:

03.10.2013 US 201361886552 P
01.08.2014 US 201462032446 P

(43)	Date of publication of application:
	10.08.2016 Bulletin 2016/32

(60)	Divisional application:
	17204999.1

(73)	Proprietor: Kura Oncology, Inc.
	San Diego, CA 92121 (US)

(72)	Inventors:
	LI, Liansheng San Diego, CA 92130 (US) WU, Tao Carlsbad, CA 92009 (US) FENG, Jun San Diego, CA 92130 (US) REN, Pingda San Diego, CA 92130 (US) LIU, Yi San Diego, CA 92130 (US)

(74)	Representative: Kremer, Simon Mark et al
	Mewburn Ellis LLP City Tower 40 Basinghall Street London EC2V 5DE City Tower 40 Basinghall Street London EC2V 5DE (GB)

(56)

References cited: :

EP-A1- 2 455 381
WO-A2-2012/170845
US-A- 3 984 556
US-A- 5 116 843
US-A1- 2010 056 800

WO-A1-2008/156739
WO-A2-2014/179154
US-A- 4 042 704
US-A1- 2008 227 767
US-B1- 6 596 726

DATABASE PUBCHEM [Online] 01 December 2012 'SCHEMBL7846632', XP055331725 Retrieved from NCBI Database accession no. CID 70205837
DATABASE PUBCHEM [Online] 04 December 2007 'SCHEMBL7879101', XP055331726 Retrieved from NCBI Database accession no. CID 18347999
TSURUO, T ET AL.: 'Platelet aggregation in the formation of tumor metastasis.' PROCEEDINGS OF THE JAPAN ACADEMY, SERIES B vol. 84, no. 6, 2008, pages 189 - 198, XP055331728 Retrieved from the Internet: <URL:https://www.jstage.jst.go.jp/artide/pj ab/84/6/84_6_189/_pdf> [retrieved on 2014-11-26]
DATABASE PUBCHEM [Online] 08 February 2007 '4A-AZONIA-5,6,7,8-TETRAHYDROANTHRACENE', XP055331729 Retrieved from NCBI Database accession no. CID 13481918

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).